Benzodiazepines and anxiety disorders: a review for the practicing physician
The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
UNLABELLED: OBJECTIVES AND SCOPE: The objective of this article is to briefly review for practicing clinicians differences among the benzodiazepines (BZDs) that are commonly used to treat anxiety, the efficacy of BZDs in various anxiety disorders, and potential safety issues associated with BZDs, including adverse events, tolerance, dependence, and withdrawal. METHODOLOGY: Information for this review was obtained using literature searches through PubMed (1966-2004), Google, and the Food and Drug Administration Catalog of Approved Drugs. Data sources were searched for information regarding anxiety disorders and the safety and efficacy of BZDs. Wherever possible and appropriate, information from randomized controlled trials was given priority. FINDINGS: Benzodiazepines have demonstrated efficacy in treating patients with anxiety disorders, with varying degrees of efficacy. Use of BZDs is advantageous because they have a quick onset of action and are generally well tolerated. Extended-release formulations of BZDs may be particularly advantageous in some patients with anxiety as they allow for maximization of a drug's therapeutic window with consistent serum drug concentrations. CONCLUSIONS: BZDs remain a mainstay in the treatment of anxiety, as both monotherapy and adjunctive therapy. Factors to consider prior to prescribing a BZD include the patient's diagnosis, as well as drug characteristics, including the potential for interactions with other drugs, the risk of dependence and withdrawal, and the required frequency of dosing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Trier Social Stress Test (TSST) is regarded as the gold standard in simulating a stressful social situation”
In the citing paper
“That previous study focused on women with SAD with baseline LSAS score ≥60; average SUDS rating during the performance of a TSST was 80.7 when treated with placebo. 9”
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Posttraumatic Stress Disorder in the National Comorbidity Survey
Kessler, R. C. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240066012 · Cited by 10,379
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
A systematic review of the associations between dose regimens and medication compliance
Claxton, A. J., Cramer, J., & Pierce, C. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80109-0 · Cited by 2,388
Psychotropic Drug Use and the Risk of Hip Fracture
Ray, W. A., Griffin, M. R., Schaffner, W., Baugh, D. K., & Melton, L. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702123160702 · Cited by 1,000
Benzodiazepines of Long and Short Elimination Half-life and the Risk of Hip Fracture
Ray, W. A. (1989) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1989.03430230088031 · Cited by 548
Newer antidepressants and the cytochrome P450 system
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.3.311 · Cited by 482
Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives.
Longo, L. P., & Johnson, B. (2000) · PubMed · Cited by 420
Rickels, K. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820230054005 · Cited by 412
Drug-Induced Cognitive Impairment in the Elderly
Moore, A. R., & O??Keeffe, S. T. (1999) · Drugs & Aging · doi:10.2165/00002512-199915010-00002 · Cited by 409
Research works printed but not linked: 9
- Rochiccioli P. Use of an anxiolytic agent: clobazam in children [in French]. Rev Int Pediatr 1977;59–62
- Disayavanish C Mahatnirunkul S Disayavanish P. Differential effects of three benzodiazepines in the treatment of neurotic patients. In: Hindmarch I Stonier PD Trimble M editors. Clobazam: Human Psychopharmacology and Clinical Applications. London: The Royal Society of Medicine; 1985. pp.81–8
- Harrison C Hindmarch I Clyde CA. A comparison of clobazam and diazepam in anxious patients. In: Hindmarch I Stonier PD Trimble M editors. Clobazam: Human Psychopharmacology and Clinical Applications. London: The Royal Society of Medicine; 1985. pp.89–100
- Thompson DJ. Comparison of drug treatment (clobazam) and relaxation therapy in the management of anxiety. Preliminary communication. In: Hindmarch I Stonier PD Trimble M editors. Clobazam: Human Psychopharmacology and Clinical Applications. London: The Royal Society of Medicine; 1985. pp.101–3
- DuPont RL, DuPont CM, DuPont Spencer E. Generalized anxiety disorder: a clinician’s guide to “the worry disease”. Dir Psychiatry 1999;XIX:133–45
- Siegfried K, Koeppen D, Taeuber K, Badian M, Malerczyk V, Sittig W. A double-blind comparison of the acute effects of clobazam and lorazepam on memory and psychomotor functions. Royal Soc Med Int Symp Ser 1981;43:13–21
- DuPont RL DuPont Spencer E DuPont CM. Anxiety and insomnia. In: The Anxiety Cure. An Eight-Step Program for Getting Well. Hoboken NJ: John Wiley & Sons; 2003. pp.200–6
- Kirkwood CK Melton ST. Anxiety disorders. In: Dipiro JT Talbert RL Yee GC Matzke GR Wells BG Posey LM editors. Pharmacotherapy: A Pathophysiologic Approach. 5th edn. Chicago: McGraw-Hill; 2002. pp.1289–310
- DuPont RL DuPont CM. Sedatives/hypnotics and benzodiazepines. In: Frances RJ Miller SI editors. Clinical Textbook of Addictive Disorders. New York: The Guilford Press; 1998. pp.120–49
Cited by
Benzodiazepines in epilepsy: Pharmacology and pharmacokinetics
Riss, J., Cloyd, J., Gates, J., & Collins, S. (2008) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2008.01004.x · Cited by 511
Earnheart, J. C., Schweizer, C., Crestani, F., Iwasato, T., Itohara, S., Mohler, H., & Lüscher, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3609-06.2007 · Cited by 203
“GABAA receptors (GABAARs) are key control elements of anxiety states based on the anxiolytic properties of benzodiazepines (BZs), which act as allosteric GABAAR agonists (Mohler et al., 2002; Kaplan and DuPont, 2005).”
BackgroundBenzodiazepine Use and Misuse Among Patients in a Methadone Program
Chen, K. W., Berger, C. C., Forde, D. P., D'Adamo, C., Weintraub, E., & Gandhi, D. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-90 · Cited by 149
Altamura, A. C., Buoli, M., Albano, A., & DellʼOsso, B. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3283384c74 · Cited by 134
Smith, A. J., & Tett, S. E. (2010) · BMC Health Services Research · doi:10.1186/1472-6963-10-321 · Cited by 82
Metadata
- Authors
- Kaplan, E. M., & DuPont, R. L.
- Affiliations
- University of South Florida (US)
- Georgetown University (US)
- Corresponding author
- Kaplan, Eric Michael
- ORCID
- DuPont, Robert L.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2005-05-12
- Volume
- 21
- Issue
- 6
- Pages
- 941-950
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2137986275
- Cited by
- 55
- References
- 106
- Citations by year
- 2025: 3 · 2024: 2 · 2023: 1 · 2022: 2 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 5 · 2014: 1 · 2013: 2 · 2012: 5
- FWCI
- 0.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and pharmacology of benzodiazepine derivatives
- Keywords
- benzodiazepines, anxiety disorders, drug tolerance, benzodiazepine dependence, benzodiazepine withdrawal, sustained-release formulation, drug interactions
- MeSH terms
- Anxiety Disorders, Benzodiazepines, Drug Tolerance, Humans, Practice Patterns, Physicians', Substance Withdrawal Syndrome, Anti-Anxiety Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benzodiazepines and anxiety disorders: a review for the practicing physician. https://app.cochat.ai/papers/10.1185/030079905x48401
- The paper
- Kaplan, E. M., & DuPont, R. L. (2005). Benzodiazepines and anxiety disorders: a review for the practicing physician. Current Medical Research and Opinion. https://doi.org/10.1185/030079905x48401
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.